Ignite Creation Date:
2025-12-25 @ 4:05 AM
Ignite Modification Date:
2026-03-01 @ 9:58 AM
Study NCT ID:
NCT03773302
Status:
TERMINATED
Last Update Posted:
2024-05-08
First Post:
2018-12-10
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations
Sponsor:
QED Therapeutics, a BridgeBio company
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2019-12-27
Start Date Type:
ACTUAL
Primary Completion Date:
2023-03-02
Primary Completion Date Type:
ACTUAL
Completion Date:
2023-03-02
Completion Date Type:
ACTUAL
First Submit Date:
2018-12-10
First Submit QC Date:
None
Study First Post Date:
2018-12-12
Study First Post Date Type:
ACTUAL
Results First Submit Date:
2023-12-20
Results First Submit QC Date:
None
Results First Post Date:
2024-05-08
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2024-04-15
Last Update Post Date:
2024-05-08
Last Update Post Date Type:
ACTUAL